Columns | Clinical Trial Insights

Successful efforts of the organ donation sector could serve as a model for rebuilding public trust.

Yesterday's SMOs have given way to a new service provider that should be recognized.

With outsourcing on the rise, it's time companies reevaluated the role of CROs.

Online trial registries alone will not succeed at rebuilding public confidence.

Lack of adequate and attentive support is preventing some sites from fully taking advantage of EDC and ePRO technologies.

A growing trend in the industry has many pharmaceutical companies looking to manage the changing mix of global clinical trial locations.

Performance, compliance, and financial pressures are hitting investigators hard. What can sponsors and CROs do to help the situation?

The FDA's Critical Path Initiative acknowledges long-standing and widely accepted challenges facing the clinical research enterprise and identifies several opportunity areas that may help to address these challenges.

Based on the numbers, sponsors will rapidly change their clinical trials midstream.